Skip to main content

UITRUCKS: CELULAS T CARS UNIVERSALES E INDUCIBLES DE CUARTA GENERACION PARA INMUNOTERAPIA DE LINFOMAS REFRACTARIOS.

PI21/00298

•
Funding agency name Instituto de Salud Carlos III
Funding agency acronym ISCIII
Program Programa Estatal de Generación de Conocimiento y Fortalecimiento del Sistema Español de I+D+I
Subprogram Subprograma Estatal de Generación de Conocimiento
Call Proyectos de Investigación en Salud
Call year 2021
State Plan 2017-2020 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre FUNDACION PUBLICA ANDALUZA PROGRESO Y SALUD
Execution centre CENTRO DE GENOMICA E INVESTIGACION ONCOLOGIA -GENYO-

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

First-in-class transactivator-free, doxycycline-inducible IL-18-engineered CAR-T cells for relapsed/refractory B cell lymphomas

  • Justicia-Lirio, Pedro
  • Tristán-Manzano, María|||0000-0001-8721-1414
  • Maldonado-Pérez, Noelia|||0000-0001-5975-0488
  • Barbero-Jiménez, Carmen
  • Cortijo-Gutiérrez, Marina|||0000-0002-0161-515X
  • Pavlovic, Kristina
  • Molina-Estevez, Francisco J.
  • Muñoz, Pilar
  • Hinckley-Boned, Ana
  • Rodriguez-Madoz, Juan Roberto|||0000-0003-4327-1866
  • Prosper, Felipe|||0000-0001-6115-8790
  • Griñán-Lison, Carmen
  • Navarro-Marchal, Saúl Abenhamar|||0000-0003-3508-6396
  • Panisello, Carla|||0000-0002-8437-4418
  • Muñoz-Ballester, Julia
  • González-Sierra, Pedro A.
  • Herrera, Concha
  • Marchal, Juan A.
  • Martín, Francisco|||0000-0003-1961-8612
Although chimeric antigen receptor (CAR) T cell therapy has revolutionized type B cancer treatment, efficacy remains limited in various lymphomas and solid tumors. Reinforcing conventional CAR-T cells to release cytokines can improve their efficacy but also increase safety concerns. Several strategies have been developed to regulate their secretion using minimal promoters that are controlled by chimeric proteins harboring transactivators. However, these chimeric proteins can disrupt the normal physiology of T cells. Here, we present the first transactivator-free anti-CD19 CAR-T cells able to control IL-18 expression (iTRUCK19.18) under ultra-low doses of doxycycline and without altering cellular fitness. Interestingly, IL-18 secretion requires T cell activation in addition to doxycycline, allowing the external regulation of CAR-T cell potency. This effect was translated into an increased CAR-T cell antitumor activity against aggressive hematologic and solid tumor models. In a clinically relevant context, we generated patient-derived iTRUCK19.18 cells capable of eradicating primary B cells tumors in a doxycycline-dependent manner. Furthermore, IL-18-releasing CAR-T cells polarized pro-tumoral macrophages toward an antitumoral phenotype, suggesting potential for modulating the tumor microenvironment. In summary, we showed that our platform can generate exogenously controlled CAR-T cells with enhanced potency and in the absence of transactivators.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

CD19 CAR-T cell therapy: a new dawn for autoimmune rheumatic diseases?

  • Rangel-Pelaez, Carlos
  • Martínez-Gutiérrez, Laura
  • Tristán-Manzano, María
  • Callejas-Rubio, José Luis
  • Ortego-Centeno, Norberto
  • Martín, Francisco
  • Martín, Javier
Autoimmune rheumatic diseases (ARDs), such as rheumatoid arthritis, systemic lupus erythematosus, and systemic sclerosis, involve dysregulated immune responses causing chronic inflammation and tissue damage. Despite advancements in clinical management, many patients do not respond to current treatments, which often show limited efficacy due to the persistence of autoreactive B cells. Chimeric antigen receptor (CAR)-T cell therapy, which has shown success in oncology for B cell malignancies, targets specific antigens and involves the adoptive transfer of genetically engineered T cells. CD19 CAR-T cells, in particular, have shown promise in depleting circulating B cells and achieving clinical remission. This review discusses the potential of CD19 CAR-T cells in ARDs, highlighting clinical achievements and addressing key considerations such as optimal target cell populations, CAR construct design, acceptable toxicities, and the potential for lasting immune reset, crucial for the safe and effective adoption of CAR-T cell therapy in autoimmune treatments., The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was supported by Cooperative Research Networks Oriented to Health Results (RICORS), Inflammatory Diseases Network (REI) (RD21/0002/0039; RD24/0007/0016) (JM). Carlos III Health Institute (ISCIII). Next Generation EU funds, which finance the actions of the Recovery, Transformation and Resilience Plan. TerAv RD21/ 0017/0004 (FM) and grant PI21/00298 (FM) funded by Instituto de Salud Carlos III (ISCIII) from the Spanish Ministry of Science and Innovation, by the Instituto de Salud Carlos III (ISCIII) and the European Regional Development Fund (FEDER), by Consejería de Salud y Familias (CSyF) -Junta de Andalucía - FEDER/European Cohesion Fund (FSE) for Andalucía: Grants: PECART-0031-2020 (FM, JAM). CR-P was funded by Grant PREP2022-000747 funded by MICIU/AEI /10.13039/501100011033 and by ESF+., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Donor insertion into CX3CR1 allows epigenetic modulation of a constitutive promoter on hematopoietic stem cells and its activation upon myeloid differentiation

  • Ramos-Hernández, Iris
  • Fuster-García, Carla
  • Aguilar-González, Araceli
  • Lozano-Vinagre, María L.
  • Guenechea-Amurrio, Guillermo
  • Sánchez-Luque, Francisco J.
  • Gonçalves, Manuel A. F. V.
  • Cathomen, Toni
  • Muñoz, P.
  • Molina-Estévez, Francisco J.
  • Martín, Francisco
To improve ex vivo gene therapy strategies involving hematopoietic stem and progenitor cells (HSPCs), we propose a novel knock-in strategy (named KI-Ep) aiming to achieve transgene regulation of the inserted cassette through the acquisition of naturally occurring epigenetic marks. Based on this hypothesis, we selected CX3CR1 (a myeloid-specific gene presenting a poised histone signature on primitive HSPCs) as safe harbor to generate KI-Ep HSPCs. We demonstrated that, unlike the expression pattern achieved with lentiviral vectors (LVs), the insertion of a constitutive expression cassette into the intron 1 of the CX3CR1 locus (CX3CR1-I) in HSPCs resulted in very low expression levels in the more primitive HSPCs but, crucially, strong expression in HSPC-differentiated populations (especially myeloid cells), both in vitro and in vivo. Furthermore, we showed that the promoter of the expression cassette inserted into CX3CR1-I acquired epigenetic marks associated with poised genes during the HSPC stage. These marks transitioned to activated histone states upon KI-Ep HSPCs differentiation. In summary, here, we introduce the KI-Ep concept which enables the epigenetic modulation of the inserted transgene during the HSPCs stem cell stages and its subsequent activation upon differentiation., This work was supported by the by the Fondo Europeo de Desarrollo Regional (FEDER), NextGenerationEU funds—actions of the Recovery and Resilience Mechanism and the Instituto de Salud Carlos III (ISCIII) through the financing research projects [PI18/00337 and PI21/00298 to F.M., and PI21/00875 to P.M.], networks (RICORS-TerAv [RD21/ 0017/0004 to F.M., P.M. and F-J.M-E.; RD21/0017/0027 to G.G-A.] and personal (FI19/00163 to I.R-H.). By the Consejería de Salud y Familias (Junta de Andalucía), under the 2019 call for “Proyectos Estratégicos I + D + I con incorporación de capital humano” [PEER-0286-2019 to P.M.] and FEDER/European Cohesion Fund (FSE) for Andalucía [PECART-0031-2020 to F.M.]; by the Consejería de Transformación Económica, Industria, Conocimiento y Universidades (Junta de Andalucía) through the EMERGIA EMERGIA2020 programe [EMERGIA20_00049 to P.M.]. By the Pompe Competitive Research Grant Program by SPARK Therapeutics [SPARK-2022-002 to F-J.M-E.]; by the Ministerio de Ciencia, Innovación y Universidades [PID2021-125077OB-C22 to G.G-A]; the Ministerio de Ciencia e innovación (MICIN)—líneas estratégicas [PLEC2021-008094 to F.M.] by Ministerio de Ciencia e innovación (MICIN), Plan de Recuperación, transformación y resilencia, Centro para el Desarrollo Tecnológico Industrial (CDTI) and European Union-Next Generation EU [00123009/SNEO-20191072 and PMPTA22/00060 to F.M.]; by the Spanish National Research Agency [AEI; grants RYC2021-031920-I and CNS2022-136033 to F-J.S-L.]. And by the European Union, Horizon Europe Framework Program through the EIC PathfinderChallenges [X-PAND 101070950 to T.C] and the European Cooperation in Science and Technology (COST) [GeneHumdi-CA21113]. Funding to pay the Open Access publication charges for this article was provided by Instituto de Salud Carlos III (ISCIII) [RD21/ 0017/0004]; Universidad de Granada/CBUA., Peer reviewed